Takeda Pharmaceutical Company Limited · TAK · FY2026 Q2 · Calendar Q4 2026
Takeda maintains FY2026 guidance as launches and savings advance
Takeda's current analysis supports a measured growth-transition story: new launches and late-stage pipeline progress are advancing, while transformation savings are offsetting modest core-revenue pressure. The evidence is constructive but execution, access and mature-portfolio risks remain material.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about TAK FY2026 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management highlighted successful ORZEYFUL and MIMRYLO launches, progress for ZASOCITINIB, and positive TAK-921 data. The transformation program generated approximately JPY 30 billion of annualized savings in H1, and FY2026 guidance was maintained with a low-single-digit revenue decline outlook and raised profit forecasts.
Guidance delta
FY2026 guidance was maintained; the analysis notes a low-single-digit revenue decline outlook and raised profit forecasts, supported by favorable FX and cost efficiencies.
Key takeaways
- Launch progress for ORZEYFUL, MIMRYLO and ZASOCITINIB is central to the growth outlook.
- TAK-921 and ENTYVIO supplied notable pipeline and clinical updates.
- Transformation savings are supporting operating profit and continued investment.
- The near-term outlook still includes modest core-revenue pressure and mature-portfolio headwinds.
Management priorities
- Commercialize ORZEYFUL in the US after DEA scheduling and continue launch execution.
- Advance ZASOCITINIB filings and development in psoriasis and inflammatory bowel disease.
- Progress TAK-921 studies while continuing transformation initiatives and reinvestment in growth.
Follow TAK with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationTakeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions.…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ALGN Align Technology, Inc. | FY2026 Q3 · Calendar Q4 2026 | +1.1% | +1.1% | Align lowers 2026 guidance as consumer demand softens |
| GKOS Glaukos Corporation | FY2026 Q3 · Calendar Q4 2026 | +587.8% | +0.1% | Glaukos raises 2026 guidance after strong Epioxa and iDose growth |
| GEHC GE HealthCare Technologies Inc. | FY2026 Q3 · Calendar Q4 2026 | +11.7% | +6.6% | GE HealthCare raises 2026 outlook as margins expand |
| LH Labcorp Holdings Inc. | FY2026 Q3 · Calendar Q4 2026 | +3.0% | +8.8% | Labcorp raises 2026 outlook as specialty testing drives Q3 growth |
| BIIB Biogen Inc. | FY2026 Q3 · Calendar Q4 2026 | +31.7% | -3.4% | Biogen’s Q3 growth broadened beyond legacy MS franchise |
| GSK GSK plc | FY2026 Q3 · Calendar Q4 2026 | +10.5% | -4.3% | GSK Q3 2026: Specialty Medicines Drive Growth as Guidance Holds |
Latest beats and misses
Who reports nextBeat on EPS
- GENFY2027 Q2 · October 28, 2026+2.9% EPS+11.2% move
- KLACFY2027 Q1 · October 28, 2026+2.5% EPS+7.3% move
- SANFY2026 Q3 · October 28, 20260.0% EPS-6.3% move
- FFY2026 Q3 · October 28, 2026+19.5% EPS+1.4% move
- EQIXFY2026 Q3 · October 28, 2026+20.0% EPS+5.4% move
- EBAYFY2026 Q3 · October 28, 2026+7.1% EPS+0.2% move
Missed on EPS
- AWKFY2026 Q3 · October 28, 2026-2.0% EPS+1.1% move
- CPFY2026 Q3 · October 28, 2026-3.2% EPS-1.9% move
- LIIFY2026 Q3 · October 28, 2026-7.1% EPS-10.6% move
- EXRFY2026 Q3 · October 27, 2026-1.7% EPS+0.1% move
- NOWFY2026 Q3 · October 28, 2026-2.0% EPS-3.0% move
- CMGFY2026 Q3 · October 28, 2026-7.1% EPS+2.7% move
Get the TAK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-29T16:06:23.804503+00:00
- FN2 earnings calendar · 2026-10-29T01:23:20.584741+00:00
- Polygon adjusted daily market bars · 2026-10-29T16:10:42.864362+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-29. For educational purposes only; not investment advice.